Skip to search formSkip to main contentSkip to account menu

1 ML certolizumab pegol 200 MG/ML Prefilled Syringe [Cimzia]

Known as: CERTOLIZUMAB PEGOL 200 mg in 1 mL SUBCUTANEOUS INJECTION, SOLUTION [Cimzia], Cimzia 200 MG in 1 ML Prefilled Syringe, Cimzia 200 MG per 1 ML Prefilled Syringe 
National Institutes of Health

Related topics

Related topics

8 relations

Broader (1)

1 ML certolizumab pegol 200 MG/ML Prefilled Syringe
CimziaPrefilled SyringeSodium AcetateSodium Chloride
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis
Certolizumab pegol (Cimzia ® ) is a PEGylated, Fab′-only, recombinant humanized antibody against TNF-α. Subcutaneous certolizumab… 
2018
2018
Anti-Tumor Necrosis Factor α Therapeutics Differentially Affect Leishmania Infection of Human Macrophages
Tumor necrosis factor α (TNFα) drives the pathophysiology of human autoimmune diseases and consequently, neutralizing antibodies… 
Review
2018
Review
2018
Structural Biology of the TNFα Antagonists Used in the Treatment of Rheumatoid Arthritis
The binding of the tumor necrosis factor α (TNFα) to its cognate receptor initiates many immune and inflammatory processes. The… 
Review
2017
Review
2017
Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation.
BACKGROUND Several biologic therapies are approved by the National Institute for Health and Care Excellence (NICE) for psoriatic… 
2017
2017
Certolizumab pegol administration devices: a profile of their use and usability
Certolizumab pegol (Cimzia®), a tumour necrosis factor-α (TNF) antagonist, is an effective and well-tolerated option for the… 
Review
2016
Review
2016
PEGylation of Biopharmaceuticals: A Review of Chemistry and Nonclinical Safety Information of Approved Drugs.
Review
2014
Review
2014
Certolizumab Pegol: A Review of Its Use in Patients with Axial Spondyloarthritis or Psoriatic Arthritis
Certolizumab pegol (Cimzia®) is a polyethylene glycolylated antigen-binding fragment of a recombinant human monoclonal antibody… 
2013
2013
Antibody fragments: Prolonging circulation half-life special issue-antibody research
Antibodies are currently the fastest growing class of therapeutic proteins. When antibody fragments are included, there are over… 
Review
2013
Review
2013
Certolizumab Pegol
Certolizumab pegol (Cimzia®) is a recombinant, polyethylene glycolylated, antigen-binding fragment of a humanized monoclonal… 
Review
2013
Review
2013
A review of cost–effectiveness evaluations as part of national health technology assessments of biologic DMARDs in the treatment of rheumatoid arthritis
Rheumatoid arthritis (RA) is an autoimmune chronic disease which is associated with an increasing disability in patients and high… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License